Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10972072 | 0.85 | CYP2D6 (0.61) | KMT2ACYP2D6MEN1LMNATP53 | |
| SCHEMBL11182937 | 0.83 | CYP2D6 (0.60) | KMT2ACYP2D6MEN1LMNATP53 | |
| SCHEMBL10972848 | 0.82 | KMT2A (0.51) | KMT2ACYP2D6LMNATP53 | |
| SCHEMBL314269 | 0.81 | KMT2A (0.47) | KMT2ACYP2D6 | |
| SCHEMBL11366526 | 0.78 | KMT2A (0.48) | KMT2ACYP2D6 | |
| SCHEMBL10971960 | 0.78 | KMT2A (0.48) | KMT2ACYP2D6 | |
| SCHEMBL10838714 | 0.76 | CYP2D6 (0.62) | KMT2ACYP2D6SMN1; SMN2MEN1LMNA | |
| SCHEMBL11179556 | 0.75 | KMT2A (0.50) | KMT2ACYP2D6MEN1LMNA | |
| Succinic Acid SCHEMBL7063254 | 0.71 | KMT2A (0.40) | KMT2ACYP2D6 | |
| SCHEMBL23641970 | 0.68 | SMN1; SMN2 (0.69) | KMT2ACYP2D6SMN1; SMN2MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | KMT2A 3273/4885CYP2D6 2886/4885SMN1; SMN2 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.